TITLE

Rivaroxaban being tested in patients with arrhythmia disorders in ROCKET AF trial

PUB. DATE
November 2008
SOURCE
Cardiology Today;Nov2008, Vol. 11 Issue 11, p11
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that the ROCKET AF clinical trial investigated the safety and efficacy of rivaroxaban compared to warfarin in treating patients with arrhythmia disorders in the U.S. The trial will involve at least 14,000 persons who will be randomly assigned to rivaroxaban or warfarin during a crossover study in 272 study centers. Since formation of blood clot is being prevented and though warfarin is effective in blood clot prevention, Dr. Yousef Mohammad hopes that the trial will result in another treatment option for patients.
ACCESSION #
35639342

 

Related Articles

  • BRIDGE. Nichols, Emma Hitt; Ortel, Thomas L. // MD Conference Express;Aug2015, Vol. 15 Issue 21, p6 

    In the BRIDGE trial, bridging with low molecular weight heparin in patients with atrial fibrillation who underwent surgery or an invasive procedure that required warfarin interruption resulted in similar rates of arterial thromboembolism but significantly higher rates of minor and major bleeding.

  • Comparison of Hemodynamic Stability between Propofol Plus Remifentanil and Isoflorane during Middle Ear Surgery by Equal Bispectral Index Signal. Hosseinzadeh, Hamzeh; sharabiani, Behzad Aliakbar; Movassagi, Reza; Panahi, Jafar Rahimi; Naderpour, Masood // Medical Journal of Tabriz University of Medical Sciences & Healt;Apr/May2012, Vol. 34 Issue 1, p13 

    Background and Objectives: Most of the middle ear surgeries are performed by using microscope and bloodless surgical field plays an important role in the vision of surgeon and consequently in the quality of surgery. There are different methods to reduce systemic blood pressure to overcome...

  • Endoscopic cyanoacrylate injection versus ß-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Mishra, Smruti Ranjan; Sharma, Barjesh Chander; Kumar, Ashish; Sarin, Shiv Kumar // Gut;Jun2010, Vol. 59 Issue 6, p8 

    The article focuses on a research study comparing the efficacy of beta-blocker treatment with cyanoacrylate injection for gastric variceal rebleeding prevention. The randomized controlled trial involved patients with gastro-oesophageal varices type 2 (GOV2) with eradicated oesophageal varices or...

  • Invivo Hemostatic Effect of Ankaferd Blood Stopper in Rat Major Renal Trauma Model: Controlled Trial of Novel Hemostatic Agent. GERMIYANOGLU, Cankon; HURI, Emre; AKGUL, Turgay; AYYILDIZ, Ali; USTUN, Huseyin // International Journal of Hematology & Oncology / UHOD: Uluslarar;Dec2010, Vol. 20 Issue 4, p206 

    Ankaferd Bloodstopper (ABS) which is a medicinal product has been approved in the control of hemorrhage externally, dental surgery bleedings in Turkey to control the bleeding in renal trauma model was evaluated. Twelve Wistar rats were divided into two groups. Group I (GI),control, Group II...

  • Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose. Leil, T. A.; Feng, Y.; Zhang, L.; Paccaly, A.; Mohan, P.; Pfister, M. // Clinical Pharmacology & Therapeutics;Sep2010, Vol. 88 Issue 3, p375 

    A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial. The exposure–response models demonstrated that an increase in daily steady-state area under the plasma...

  • The latest drug news. Ray, Sarah C. // Pharmacy Today;Aug2013, Vol. 19 Issue 8, p16 

    The article discusses the clinical trial of apixaban or conventional therapy with enoxaparin followed by warfarin in treating patients with acute venus thromboembolism (VTE). It shows that apixaban was noninferior to conventional treatment for both relative risk and difference in risk, with...

  • Between the Devil and the Deep Blue Sea--balancing the risks and potential benefits of warfarin for older people with atrial fibrillation. Morgan, Sophie Victoria // Age & Ageing;Nov2004, Vol. 33 Issue 6, p544 

    Presents a case study which assessed the risks and benefits of warfarin for older people with atrial fibrillation (AF). Outcome of clinical trials on antithrombotic therapy in AF patients; Evaluation of thromboembolic risk among individuals with AF; Efficacy of warfarin.

  • Apixaban trial results look promising. Elliott, William T. // Neurology Alert;Oct2011 Clinical Briefs, p1 

    The article discusses the results of the ARISTOTLE trial with the use of apixaban for the prevention of stroke in patients with atrial fibrillation (AF). The ARISTOTLE trial had a primary outcome of ischemic or hemorrhagic stroke, or systemic embolism. After median follow-up, the primary outcome...

  • DC shock: spontaneous reversion to sinus rhythm during anaesthesia with propanidid. Vecht, R.J.; Galley, R.; Goodwin, P. // British Medical Journal;10/18/1975, Vol. 4 Issue 5989, p143 

    Presents cases of spontaneous reversion of arrhythmia to sinus rhythm after injection of propanidid. Medical history of the patients; Ability of the drug to depress the conducting system of the heart; Effect of dose or rate of infusion on the antiarrhythmic action of the drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics